 |
您当前的位置：电子期刊栏目→论著>>正文 |
| 非小细胞肺癌患者血清miR-133b的表达水平及其临床意义探讨 |
| 作者：冯晓云1 葛琴1 陆志斌2 |
| 单位：1. 南通市肿瘤医院 检验科, 江苏 南通 226361; 2. 南京市浦口区中心医院 胸外科, 江苏 南京 211800 |
| 关键词：非小细胞肺癌 miR-133b 表达 生存率 |
| 分类号：R734.2 |
| 出版年·卷·期（页码）：2015·34·第六期（934-937） |
| 摘要： |
目的:探讨非小细胞肺癌患者血清miR-133b的表达水平与临床病理特征及疾病预后的关系.方法:将80例经病理活检证实为非小细胞肺癌患者纳入此次研究的对象,同期选取进行体检的健康人群80例作为正常对照组,采用real-time荧光定量PCR方法检测所有人员血清miR-133b的表达水平,进一步分析非小细胞肺癌患者血清miR-133b的表达水平与患者的临床及病理特征的关系.结果:非小细胞肺癌患者血清miR-133b表达水平(0.86±1.27)显著低于正常对照组的表达水平(1.78±1.36),差异具有统计学意义(t=9.572,P=0.004).非小细胞肺癌患者血清miR-133b的表达水平与病理分期、肿瘤分化程度、抽烟史及是否发生淋巴结转移等因素密切相关(P<0.05),与患者年龄、性别、肿瘤直径及病理分型无关(P>0.05);非小细胞肺癌患者术后miR-133b高表达者1年内的生存率(73.8%)明显高于miR-133b低表达者(52.6%),差异具有统计学意义(χ2=8.580,P=0.003).结论:血清miR-133b的检测有助于早期对非小细胞肺癌进行筛选与诊断,其表达与非小细胞肺癌临床及病理特征、治疗后存活时间具有明显的相关性,对评估非小细胞肺癌的预后具有一定价值. |
Objective: To explore the relationship between serum miR-133b levels and clinical pathological characteristics,as well as prognosis of disease in non-small cell lung cancer patients. Methods: A total of 80 patients were diagnosed as non-small cell lung cancers by pathological biopsy were included in this study. Meanwhile, 80 health people underwent health examinations were selected as controls. The levels of serum miR-133b were measured by real-time PCR. Results: The serum miR-133b level in non-small cell lung cancer patients was (0.86±1.27), which was obviously lower than that of the normal controls (1.78±1.36) (t=9.572, P=0.004), and the differences had significance (P< 0.05). The serum miR-133b levels were related to the pathologic stage, tumor differentiation grade, smoking history and lymph node metastasis (P<0.05). The patients with high expression of serum miR-133b levels had greater 1-year survival rates than those of the low expression of serum miR-133b patients (52.6%) (χ2=8.580, P=0.003). Conclusion: Detection of serum miR-133b levels is beneficial for early screening and diagnosing non-small cell lung cancers. Closely related to the clinical pathological characteristics, survival times after treatment, it is a valuable tool for evaluating the prognosis of non-small cell lung cancer patients. |
| 参考文献： |
[1] TRIOZZI P L,ACHBERGER S,ALDRICH W,et al.Differential immunologic and microRNA effects of 2 dosing regimens of recombinant human granulocyte/macrophage colony stimulating factor[J].Immunother,2012,35(7):587-594. |
| 服务与反馈： |
| 【文章下载】【发表评论】【查看评论】【加入收藏】 |
| 提示：您还未登录，请登录！点此登录 |
|
|||
|
|